# Cholera Vaccine Market

> Cholera Vaccine Market Research Report: Size, Share, Trend Analysis By Vaccine Type (Inactivated Cholera Vaccine, Live Attenuated Cholera Vaccine, Oral Cholera Vaccine), By Administration Route (Oral, Injectable), By Distribution Channel (Hospitals, Pharmacies, Health Clinics, Online Pharmacies), By Target Population (Children, Adults, Travelers) andBy Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.62%
- **2024:** $ 0.66 Billion
- **2025:** $ 0.7 Billion
- **2035:** $ 1.2 Billion
- **Key Players:** Sanofi (FR), GlaxoSmithKline (GB), Merck & Co.(US), Pfizer (US), Serum Institute of India (IN), Biovac (ZA), Vabiotech (VN), Eubiologics (KR)

**Report ID:** MRFR/HC/40118-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/cholera-vaccine-market-41782

---

## Market Summary

## **Cholera Vaccine Market Overview**

As per MRFR analysis, the Cholera Vaccine Market Size was estimated at 0.62 (USD Billion) in 2023. The Cholera Vaccine Market Industry is expected to grow from 0.66(USD Billion) in 2024 to 1.2 (USD Billion) by 2035. The Cholera Vaccine Market CAGR (growth rate) is expected to be around 5.62% during the forecast period (2025 - 2035).

### **Key Cholera Vaccine Market Trends Highlighted**

The Cholera Vaccine Market is driven by increasing outbreaks of cholera, primarily in regions with poor sanitation and limited access to clean water. The urgent need for effective vaccination strategies in response to these public health challenges propels the market growth. Enhanced awareness about cholera prevention and management, alongside governmental and non-governmental initiatives for vaccination programs, further emphasizes the importance of these vaccines.

The push towards improved healthcare infrastructure in developing nations provides an additional impetus for vaccine distribution. There are numerous opportunities to be explored within this market. The rising demand for advanced vaccine technologies, including oral cholera vaccines, can lead to innovative product development. Collaborations between public health organizations and pharmaceutical companies could result in increased accessibility and affordability of vaccines in underserved regions.

Moreover, increasing investment in research and development can pave the way for developing more effective vaccines that cater to diverse strains of the cholera bacterium.  Recent times have seen a trend focusing on community engagement in vaccination efforts, particularly in high-risk areas. Public health campaigns that emphasize education about cholera prevention are gaining traction.

Additionally, there is a growing trend towards the use of digital platforms to enhance awareness and vaccination coverage. The emphasis on sustainability in healthcare also encourages eco-friendly production methods for vaccines. Overall, these trends contribute to a dynamic landscape in the cholera vaccine market that aims to address public health needs effectively and efficiently.

 Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Cholera Vaccine Market Drivers**

### **Increasing Incidence of Cholera Outbreaks**

The key factor contributing to the growth of the Cholera Vaccine Market Industry is the increasing number of cholera outbreaks, especially in less developed nations. The World Health Organization (WHO) states that cholera continues to be one of the major international health concerns, as the occurrence yearly reaches up to millions of cases. This sort of situation only serves to fan the flames for more vigorous vaccination strategies aimed at averting infections and safeguarding susceptible communities.

Owing to the cholera outbreaks, there was a need for governments and global health organizations to support the introduction and distribution of cholera vaccines which are already available on the market. There is an increasing amount of risk, which has led to the enactment of vaccination programs and implementation of them in certain geographical areas to try and control the outbreak and solve the underlying issue of high death rates. Further, there is an increased consciousness of the merit of cholera vaccines which enhances the uptake of the vaccines.

Such awareness is deepened through educational approaches held by health organizations, which advocate for vaccination as the primary intervention against cholera. Furthermore, international initiatives addressing the restricted availability of vaccines to low and middle-income countries enhance the delivery and administration of cholera vaccines, which in turn helps to boost the expansion of the Cholera Vaccine Market. In addition, the emphasis on immunization covers not only the management of existing outbreaks but also aims to eradicate cholera as a public health threat in the foreseeable future.

### **Government Initiatives and Funding**

Government initiatives and funding are crucial drivers for growth in the Cholera Vaccine Market Industry. Many countries are recognizing the importance of immunization in combating infectious diseases like cholera. As a result, governments are allocating significant resources towards vaccination programs, enhancing their healthcare infrastructure, and collaborating with international organizations. These initiatives ensure a steady supply and availability of cholera vaccines, especially in endemic and epidemic-prone regions, supporting the overall market expansion.

### **Advancements in Vaccine Technology**

Technological advancements in vaccine formulation and production are propelling the Cholera Vaccine Market Industry forward. Ongoing research and development efforts are yielding more effective vaccines with improved safety profiles and efficacy. Novel delivery mechanisms and formulations, such as oral vaccines, are making vaccination more accessible and acceptable, especially in areas with logistical challenges. This innovation is expected to enhance inoculation rates and contribute to market growth significantly.

## **Cholera Vaccine Market Segment Insights**

### **Cholera Vaccine Market Vaccine Type Insights  **

In the Cholera Vaccine Market, the segmentation by Vaccine Type reveals distinct categories that contribute to the overall market dynamics. By 2024, the Inactivated Cholera Vaccine will be valued at 0.25 USD Billion, showcasing its critical role in vaccination strategies. This type is significant as it provides a robust immunity response without risking active disease, making it a major choice in cholera-endemic regions. By 2035, this segment is expected to grow to 0.45 USD Billion, reflecting an increasing demand for effective cholera prevention measures.

Following this, the Live Attenuated Cholera Vaccine, valued at 0.2 USD Billion in 2024, serves as a vital alternative, especially in vaccination campaigns where ease of administration matters. This vaccine type is anticipated to reach 0.35 USD Billion by 2035, indicating its integral position in public health efforts due to its ability to induce long-lasting immunity with a single dose, which is crucial in outbreak scenarios. The Oral Cholera Vaccine also plays a notable role in the market, holding a value of 0.21 USD Billion in 2024 and is projected to expand to 0.4 USD Billion by 2035.

This category is particularly significant as it facilitates easier distribution and administration, especially in resource-limited settings, making it a preferred choice for mass immunization programs. Each of these vaccine types contributes uniquely to the comprehensive strategy of cholera prevention, addressing the diverse needs of populations at risk. The growth in these segments reflects a broader trend towards enhanced immunization efforts globally, driven by increased awareness of cholera's impact and proactive health measures.

As a result, the Cholera Vaccine Market revenue is expected to see robust growth, driven by these pivotal vaccine types that meet the varying demands of healthcare providers and affected populations alike.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Cholera Vaccine Market Administration Route Insights  **

The Administration Route in the Cholera Vaccine Market plays a critical role in enhancing vaccine delivery, thus impacting overall market growth. By 2024, the market is expected to be valued at 0.66 USD Billion, indicating a robust demand for effective cholera prevention mechanisms. The Administration Route is primarily divided into Oral and Injectable, with the Oral route often favored due to its ease of administration and patient compliance, making it a practical choice in many endemic regions.

This segment dominates due to its ability to deliver vaccines efficiently, especially in areas with logistical challenges. The Injectable route, while significant, is generally preferred in situations requiring swift immunity response or where Oral administration may not be feasible. The market growth is driven by increasing cholera outbreaks, the push for better [healthcare cloud infrastructure](../../../reports/healthcare-cloud-infrastructure-market-29589), and rising awareness of preventive measures.

Moreover, opportunities exist in technological advancements that improve vaccine formulation and delivery methods, addressing challenges in vaccine storage and transportation. Overall, the Administration Route is pivotal in strategizing the Cholera Vaccine Market revenue, fueling market dynamics and shaping future trends.

### **Cholera Vaccine Market Distribution Channel Insights  **

The Cholera Vaccine Market, valued at 0.66 USD Billion in 2024, showcases significant distribution channel dynamics influencing market growth. The healthcare sector encompasses key players such as hospitals, pharmacies, health clinics, and online pharmacies, each contributing to the overall market framework. Among these, hospitals play a crucial role in delivering vaccines to a large patient base and significantly driving demand. Pharmacies also hold a substantial market presence, providing widespread access to cholera vaccines, which is essential for public health initiatives.

Health clinics are vital for localized vaccination efforts, catering mainly to at-risk populations and ensuring immediate availability. Online pharmacies have emerged as an important distribution channel, extending reach and convenience for consumers, especially in remote areas. Such diverse channels ensure optimal vaccine availability and accessibility, fostering increased immunization rates and supporting overall public health strategies against cholera. As the market evolves, factors such as technological advancements and increasing awareness about cholera prevention are expected to further enhance the performance of these distribution channels, ultimately contributing to the growth of the Cholera Vaccine Market revenue.

### **Cholera Vaccine Market Target Population Insights  **

The Cholera Vaccine Market focuses on various target populations, primarily categorized into children, adults, and travelers. This market is crucial as cholera remains a significant health risk, particularly in regions with inadequate sanitation. In 2024, the Cholera Vaccine Market is expected to be valued at 0.66 USD Billion, reflecting the ongoing response to cholera outbreaks. Children represent a particularly important demographic, as they are often more vulnerable to severe dehydration caused by cholera, necessitating effective vaccination strategies.

Additionally, adults, especially those in endemic areas or serving as caregivers, play a vital role in controlling the spread of the disease. Travelers, who may visit cholera-prone regions, are another significant population; their vaccination is pivotal in preventing outbreaks and protecting public health. The ongoing growth in the Cholera Vaccine Market revenue is driven by increasing awareness of the disease and preventive measures, as well as rising healthcare initiatives targeting these specific populations. As public health efforts intensify, the Cholera Vaccine Market statistics illustrate the growing need for tailored vaccination programs focused on vulnerable groups.

### **Cholera Vaccine Market Regional Insights  **

The Cholera Vaccine Market is experiencing notable growth on a regional level, with a projected market valuation of 0.66 USD Billion in 2024. Among the regions, the APAC segment holds a significant market share, valued at 0.25 USD Billion in 2024 and expected to grow to 0.45 USD Billion in 2035, dominated by a high prevalence of cholera outbreaks and increasing healthcare initiatives. North America follows with a valuation of 0.15 USD Billion in 2024, driven by advanced healthcare frameworks and a focus on preventive measures.

Europe also contributes to the market, with a valuation of 0.12 USD Billion in 2024, reflecting strong public health policies.

South America maintains a smaller share with 0.09 USD Billion in 2024, showing potential for growth due to rising awareness and government support for vaccination programs. Meanwhile, the MEA region, valued at 0.05 USD Billion in 2024, illustrates a need for improvement in vaccine accessibility, which presents both challenges and opportunities for market growth. The diverse regional dynamics highlight significant opportunities in addressing cholera through vaccination efforts across varying healthcare systems and outbreak prevalence.

 Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Cholera Vaccine Market Key Players and Competitive Insights**

The Cholera Vaccine Market is characterized by a dynamic landscape where various stakeholders compete to provide effective solutions for cholera prevention and control. This market is shaped by factors such as rising cholera outbreaks, increasing awareness regarding the importance of vaccination, and ongoing research into new vaccine formulations. Key players are leveraging innovation, strategic partnerships, and expansion into emerging markets to enhance their competitive edge. Regulatory approvals and the push for better healthcare accessibility further contribute to the competitive dynamics within this sector.

Understanding the strengths and strategies of leading companies in the market provides valuable insights into their roles and influence on global cholera vaccination efforts. GSK has established a formidable position in the Cholera Vaccine Market, bolstered by its robust research and development capabilities and a strong portfolio of innovative vaccines.

The company is known for its commitment to addressing global health challenges, including cholera, and has invested significantly in vaccine development and distribution. GSK’s ability to engage in strategic collaborations with governments and health organizations allows it to enhance its market presence and accessibility. Additionally, GSK's high-quality product offerings that undergo rigorous testing and validation contribute to its reputation and success within this market. Furthermore, the company’s global reach facilitates the deployment of vaccines in various regions, ensuring that vulnerable populations have access to cholera vaccines, thus strengthening its standing as a leader in cholera prevention.

Haffkine BioPharmaceutical Corporation plays a pivotal role in the Cholera Vaccine Market, particularly in the context of developing countries, which are often at risk of cholera outbreaks. The company's focus on producing affordable and effective vaccines caters specifically to the needs of populations that face significant health threats from cholera. Haffkine BioPharmaceutical's long-standing expertise in vaccine technology, paired with its commitment to enhancing public health, empowers it to contribute meaningfully to cholera prevention strategies. The organization has built a strong reputation for reliability and accountability in vaccine production, further reinforcing its influence in the market.

By aligning its operational strategies with public health objectives and responding swiftly to outbreak emergencies, Haffkine BioPharmaceutical Corporation has positioned itself as a key player in easing the burden of cholera in affected regions.

### **Key Companies in the Cholera Vaccine Market Include**

- GSK
- Haffkine BioPharmaceutical Corporation
- Merck
- Takeda
- Sanofi
- CSL Limited
- Pfizer
- AstraZeneca
- Sevapharma
- **[Valneva](https://valneva.com/products/dukoral/)**
- EuBiologics
- Bharat Biotech
- Institute Pasteur
- Vaccine Development Lab

## **Cholera Vaccine Industry Developments**

- **Q2 2024: Oral cholera vaccine supply gets boost as demand surges globally** In April 2024, the World Health Organization prequalified a new oral cholera vaccine, Euvichol-S, developed by EuBiologics. The company will begin producing Euvichol-S in 2024, with a new manufacturing plant expected to reach full capacity in 2025, increasing global supply significantly.
- **Q2 2024: Millions at risk from cholera due to lack of clean water, soap and toilets and shortage of cholera vaccine** In March 2024, WHO announced that global cholera vaccine production capacity is forecast to be 37-50 million doses in 2024, with only one manufacturer, EuBiologics, currently producing the vaccine. WHO called for urgent scale-up and fast-tracking of new manufacturers, with additional entrants not expected before 2025.

## **Cholera Vaccine Market Segmentation Insights**

### **Cholera Vaccine Market Vaccine Type Outlook**

- Inactivated Cholera Vaccine
- Live Attenuated Cholera Vaccine
- Oral Cholera Vaccine

### **Cholera Vaccine Market Administration Route Outlook**

- Oral
- Injectable

### **Cholera Vaccine Market Distribution Channel Outlook**

- Hospitals
- Pharmacies
- Health Clinics
- Online Pharmacies

### **Cholera Vaccine Market Target Population Outlook**

- Children
- Adults
- Travelers

### **Cholera Vaccine Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Innovations in Vaccine Technology

Innovations in vaccine technology are transforming the Cholera Vaccine Market. Recent advancements have led to the development of more effective and easier-to-administer vaccines, which could enhance immunization coverage. For instance, the introduction of oral cholera vaccines has simplified the vaccination process, making it more appealing to populations in endemic areas. Market data suggests that these innovations may lead to increased acceptance and uptake of cholera vaccines, thereby driving market growth. The Cholera Vaccine Market stands to benefit from these technological advancements, as they align with the goal of eradicating cholera through improved vaccination strategies.

### Government Initiatives and Funding

Government initiatives aimed at combating cholera outbreaks play a crucial role in driving the Cholera Vaccine Market. Many countries have implemented vaccination programs supported by substantial funding to ensure access to vaccines in vulnerable populations. For instance, recent data suggests that countries with robust vaccination campaigns have seen a significant decline in cholera cases. This proactive approach not only enhances public health but also stimulates market growth, as increased funding leads to higher procurement of vaccines. The Cholera Vaccine Market is likely to experience a surge in demand as governments prioritize cholera prevention in their health agendas.

### Emerging Markets and Economic Growth

Emerging markets are witnessing economic growth, which is likely to influence the Cholera Vaccine Market positively. As economies develop, there is often an increase in healthcare spending, including investments in vaccination programs. Countries with improving infrastructure and healthcare systems are more capable of implementing effective cholera vaccination strategies. Market analysis suggests that regions experiencing economic uplift are also seeing a rise in vaccine accessibility and uptake. This trend indicates a potential for substantial growth in the Cholera Vaccine Market as more individuals gain access to preventive healthcare.

### Rising Travel and Migration Patterns

The increase in travel and migration patterns contributes to the dynamics of the Cholera Vaccine Market. As populations move across regions, the risk of cholera transmission escalates, particularly in areas with inadequate sanitation. This situation creates a pressing need for vaccination among travelers and migrants. Data indicates that regions experiencing high levels of migration have reported a corresponding rise in cholera cases, underscoring the necessity for preventive measures. Consequently, the Cholera Vaccine Market may see a boost in demand as health authorities recommend vaccinations for those traveling to endemic areas.

### Increasing Awareness of Cholera Prevention

The rising awareness regarding cholera prevention strategies is a pivotal driver for the Cholera Vaccine Market. Educational campaigns by health organizations and governments have emphasized the importance of vaccination in reducing cholera outbreaks. This heightened awareness is likely to lead to increased vaccination rates, particularly in high-risk regions. As a result, the demand for cholera vaccines is expected to grow, with projections indicating a potential market expansion of approximately 5% annually over the next few years. The Cholera Vaccine Market is thus positioned to benefit from this trend, as more individuals seek preventive measures against this waterborne disease.

## Future Outlook

The Cholera Vaccine Market is projected to grow at a 5.62% CAGR from 2025 to 2035, driven by increasing vaccination initiatives and rising awareness of cholera prevention.

**New opportunities:**

- Expansion of mobile vaccination units in remote areas. Development of combination vaccines targeting multiple diseases. Partnerships with NGOs for large-scale vaccination campaigns.

By 2035, the market is expected to be robust, driven by innovative strategies and increased global health initiatives.

## Segment Insights

### By Type: Inactivated Cholera Vaccine (Largest) vs. Oral Cholera Vaccine (Fastest-Growing)

The Cholera Vaccine Market is segmented into three primary types: Inactivated Cholera Vaccine, Live Attenuated Cholera Vaccine, and Oral Cholera Vaccine. Among these, the Inactivated Cholera Vaccine holds the largest market share, appealing primarily to those seeking established and reliable protection against cholera. The Oral Cholera Vaccine, however, is rapidly growing in popularity due to its ease of administration and increasing acceptance in mass vaccination campaigns, making it a significant player in the market's future.

Vaccine Type: Inactivated Cholera Vaccine (Dominant) vs. Oral Cholera Vaccine (Emerging)

The Inactivated Cholera Vaccine is characterized by its traditional approach, utilizing killed bacteria to stimulate an immune response. This method has a long history of effectiveness and is preferred in settings where a robust and immediate immune response is essential. In contrast, the Oral Cholera Vaccine, as an emerging option, leverages the convenience of oral administration, significantly enhancing accessibility and compliance among populations at risk. This segment is experiencing growth driven by changing healthcare strategies focused on improving vaccine coverage in endemic areas, highlighting a shift towards more user-friendly vaccination methods.

### By Administration Route: Oral (Largest) vs. Injectable (Fastest-Growing)

In the Cholera Vaccine Market, the distribution of market share between the two primary administration routes is notable. The oral cholera vaccines dominate the market, primarily due to their ease of administration, favorable uptake among populations, and longstanding usage history. In contrast, while injectable vaccines hold a smaller market share, they are gaining attention for their potential effectiveness in specific demographics, especially in high-risk groups. This distribution reflects the adaptive strategies employed by healthcare providers in addressing cholera outbreaks worldwide. Recent trends indicate that the injectable cholera vaccine segment is growing the fastest, driven by advancements in formulation and storage that make them more viable in challenging environments. This growth is further pushed by rising awareness among healthcare providers and patients regarding the advantages of injectable options in high-transmission settings. Moreover, government initiatives and support for vaccination programs against cholera are influencing the overall growth trajectory of both segments, with an emphasis on enhancing accessibility and acceptance among at-risk populations.

Administration Route: Oral (Dominant) vs. Injectable (Emerging)

The oral cholera vaccine segment is considered dominant in the market due to its widespread acceptance and ease of use, which allows for mass immunization campaigns. These vaccines, often requiring fewer dosages and no need for medical personnel to administer, can be distributed within community programs successfully. Conversely, the injectable cholera vaccine is emerging as a significant player, particularly for targeted vaccination efforts in areas with high incidence rates. With strong efficacy and safety profiles, this segment is attracting investments in research and development, focusing on improving storage stability and reducing side effects for a more extensive reach across varied populations. Both routes play critical roles in comprehensive cholera prevention strategies, contributing to a multifaceted approach in managing outbreaks.

### By Distribution Channel: Hospitals (Largest) vs. Online Pharmacies (Fastest-Growing)

In the Cholera Vaccine Market, distribution channels play a crucial role in accessibility and availability. Hospitals remain the largest segment, capturing a significant portion of the market share due to their established infrastructure and the urgent need for vaccinations in outbreak settings. [Pharmacies](https://www.marketresearchfuture.com/reports/pharmacy-market-12003) and health clinics also contribute notably, with health clinics being preferred for their community-based services and pharmacies offering easier access to the public. However, online pharmacies are gaining momentum, driven by the increasing trend of e-commerce and the demand for convenient healthcare solutions.

Health Clinics (Dominant) vs. Pharmacies (Emerging)

Health clinics are becoming the dominant force in the Cholera Vaccine Market, particularly due to their focused patient outreach and personalized services. These clinics often serve vulnerable populations and are instrumental in public health initiatives, making vaccinations accessible and appealing. On the other hand, pharmacies are emerging as a competitive segment, expanding their role in vaccine distribution. Enabled by advancements in digital health and customer engagement, pharmacies are increasingly providing vaccines alongside other health services. The strategic positioning of both segments highlights their vital roles in enhancing vaccination rates and meeting public health challenges.

### By Target Population: Children (Largest) vs. Travelers (Fastest-Growing)

In the Cholera Vaccine Market, the target population segments reveal a distinct distribution of market share. Children represent the largest share due to ongoing immunization programs and targeted health initiatives aimed at this vulnerable group. Adults also have a significant share, but with various vaccination needs arising out of international travel and exposure, their market position is more dynamic. Interestingly, the segment of travelers is gaining traction, influenced by the growing trend of global travel and increasing awareness about vaccine-preventable diseases.

Children (Dominant) vs. Travelers (Emerging)

Children are considered the dominant segment in the Cholera Vaccine Market due to public health campaigns and government-mandated vaccination schedules aimed at preventing cholera outbreaks. This demographic is crucial as they are often at higher risk for severe dehydration and complications caused by cholera. Conversely, the travelers segment is emerging rapidly as more individuals seek vaccination before entering areas with known cholera risks. This growing concern about health safety while traveling, coupled with increased global mobility, has positioned travelers as a fast-growing segment. Both groups reflect unique demands in vaccine distribution and education, necessitating tailored approaches from healthcare providers.

## Regional Market Share Analysis

The Cholera Vaccine Market is experiencing notable growth on a regional level, with a projected market valuation of 0.66 USD Billion in 2024. Among the regions, the APAC segment holds a significant market share, valued at 0.25 USD Billion in 2024 and expected to grow to 0.45 USD Billion in 2035, dominated by a high prevalence of cholera outbreaks and increasing healthcare initiatives. North America follows with a valuation of 0.15 USD Billion in 2024, driven by advanced healthcare frameworks and a focus on preventive measures.

Europe also contributes to the market, with a valuation of 0.12 USD Billion in 2024, reflecting strong public health policies.

South America maintains a smaller share with 0.09 USD Billion in 2024, showing potential for growth due to rising awareness and government support for vaccination programs. Meanwhile, the MEA region, valued at 0.05 USD Billion in 2024, illustrates a need for improvement in vaccine accessibility, which presents both challenges and opportunities for market growth. The diverse regional dynamics highlight significant opportunities in addressing cholera through vaccination efforts across varying healthcare systems and outbreak prevalence.

 Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## Competitive Benchmarking

The Cholera Vaccine Market is characterized by a dynamic landscape where various stakeholders compete to provide effective solutions for cholera prevention and control. This market is shaped by factors such as rising cholera outbreaks, increasing awareness regarding the importance of vaccination, and ongoing research into new vaccine formulations. Key players are leveraging innovation, strategic partnerships, and expansion into emerging markets to enhance their competitive edge. Regulatory approvals and the push for better healthcare accessibility further contribute to the competitive dynamics within this sector.Understanding the strengths and strategies of leading companies in the market provides valuable insights into their roles and influence on global cholera vaccination efforts. GSK has established a formidable position in the Cholera Vaccine Market, bolstered by its robust research and development capabilities and a strong portfolio of innovative vaccines.The company is known for its commitment to addressing global health challenges, including cholera, and has invested significantly in vaccine development and distribution. GSK’s ability to engage in strategic collaborations with governments and health organizations allows it to enhance its market presence and accessibility. Additionally, GSK's high-quality product offerings that undergo rigorous testing and validation contribute to its reputation and success within this market. Furthermore, the company’s global reach facilitates the deployment of vaccines in various regions, ensuring that vulnerable populations have access to cholera vaccines, thus strengthening its standing as a leader in cholera prevention.Haffkine BioPharmaceutical Corporation plays a pivotal role in the Cholera Vaccine Market, particularly in the context of developing countries, which are often at risk of cholera outbreaks. The company's focus on producing affordable and effective vaccines caters specifically to the needs of populations that face significant health threats from cholera. Haffkine BioPharmaceutical's long-standing expertise in vaccine technology, paired with its commitment to enhancing public health, empowers it to contribute meaningfully to cholera prevention strategies. The organization has built a strong reputation for reliability and accountability in vaccine production, further reinforcing its influence in the market.By aligning its operational strategies with public health objectives and responding swiftly to outbreak emergencies, Haffkine BioPharmaceutical Corporation has positioned itself as a key player in easing the burden of cholera in affected regions.

## Recent News & Developments

- **Q2 2024: Oral cholera vaccine supply gets boost as demand surges globally** In April 2024, the World Health Organization prequalified a new oral cholera vaccine, Euvichol-S, developed by EuBiologics. The company will begin producing Euvichol-S in 2024, with a new manufacturing plant expected to reach full capacity in 2025, increasing global supply significantly.
- **Q2 2024: Millions at risk from cholera due to lack of clean water, soap and toilets and shortage of cholera vaccine** In March 2024, WHO announced that global cholera vaccine production capacity is forecast to be 37-50 million doses in 2024, with only one manufacturer, EuBiologics, currently producing the vaccine. WHO called for urgent scale-up and fast-tracking of new manufacturers, with additional entrants not expected before 2025.

## Report Scope

| MARKET SIZE 2024 | 0.66(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.6971(USD Billion) |
| MARKET SIZE 2035 | 1.204(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.62% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Sanofi (FR), GlaxoSmithKline (GB), Merck & Co. (US), Pfizer (US), Serum Institute of India (IN), Biovac (ZA), Vabiotech (VN), Eubiologics (KR) |
| Segments Covered | Vaccine Type, Administration Route, Distribution Channel, Target Population, Regional |
| Key Market Opportunities | Emerging technologies in vaccine delivery enhance accessibility in the Cholera Vaccine Market. |
| Key Market Dynamics | Rising demand for cholera vaccines driven by increased awareness and regulatory support for preventive healthcare measures. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Cholera Vaccine Market as of 2024?**
A: The Cholera Vaccine Market was valued at 0.66 USD Billion in 2024.

**Q: What is the projected market valuation for the Cholera Vaccine Market in 2035?**
A: The market is projected to reach 1.204 USD Billion by 2035.

**Q: What is the expected CAGR for the Cholera Vaccine Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Cholera Vaccine Market during 2025 - 2035 is 5.62%.

**Q: Which companies are the key players in the Cholera Vaccine Market?**
A: Key players include Sanofi, GlaxoSmithKline, Merck & Co., Pfizer, Serum Institute of India, Biovac, Vabiotech, and Eubiologics.

**Q: What are the different types of cholera vaccines available in the market?**
A: The market includes Inactivated Cholera Vaccine, Live Attenuated Cholera Vaccine, and Oral Cholera Vaccine.

**Q: How does the valuation of Oral Cholera Vaccine compare to other types in 2024?**
A: In 2024, the Oral Cholera Vaccine was valued at 0.31 USD Billion, higher than both Inactivated and Live Attenuated types.

**Q: What distribution channels are utilized for cholera vaccines?**
A: Distribution channels include Hospitals, Pharmacies, Health Clinics, and Online Pharmacies.

**Q: What is the market valuation for cholera vaccines administered orally versus injectables?**
A: In 2024, both Oral and Injectable cholera vaccines were valued at 0.33 USD Billion, with Oral projected to grow to 0.66 USD Billion by 2035.

**Q: Which target populations are primarily served by the Cholera Vaccine Market?**
A: The primary target populations include Children, Adults, and Travelers, with valuations ranging from 0.21 to 0.45 USD Billion.

**Q: How is the market for cholera vaccines expected to evolve by 2035?**
A: The market is anticipated to grow significantly, with various segments showing potential increases in valuation by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cholera-vaccine-market-41782*